Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford spinout EvOx Therapeutics will harness the body's own precision communications system to deliver drugs to specific parts of the body, with the aim of treating conditions which are currently untreatable – including those affecting the brain, as well as autoimmune diseases and cancers.

EvOx has raised £10m in seed funding from investment company Oxford Sciences Innovation to move the technology through pre-clinical and early clinical trials.

The Oxford team has been led by DPAG's Professor Matthew Wood and Dr Samir El Andaloussi, Research Fellow at Oxford and Assistant Professor at Sweden's Karolinska Institutet. They found that by using the body's own mini-transporters – tiny circular nanostructures which shuttle materials between cells – they are able to smuggle drug therapies into the brain, targeting new treatments to the correct tissues.

Read more here.

Similar stories

Oxford-led research maps milestone stage of human development for the first time

Scientists have shed light on an important stage of early embryonic development that has never been fully mapped out in humans before.

Mapping uncharted networks in the progression of Parkinson’s

A major new $9 million project funded by the Aligning Science Across Parkinson’s (ASAP) initiative will map the original circuits vulnerable to Parkinson’s on an unprecedented scale. The project is a collaboration between core investigators Stephanie Cragg, Richard Wade-Martins, and Peter Magill at Oxford, Mark Howe at Boston University and Dinos Meletis at the Karolinska Institutet, as well as collaborators Yulong Li at Peking University and Michael Lin at Stanford University.

Drug could help diabetic hearts recover after a heart attack

New research led by Associate Professor Lisa Heather has found that a drug known as molidustat, currently in clinical trials for another condition, could reduce risk of heart failure after heart attacks.

Blood bank storage can reduce ability of transfusions to treat anaemia

New research from the Swietach Group in collaboration with NHS Blood and Transplant has demonstrated that the process of storing blood in blood banks can negatively impact the function of red blood cells and consequently may reduce the effectiveness of blood transfusions, a treatment commonly used to combat anaemia.

Overlapping second messengers increase dynamic control of physiological responses

New research from the Parekh and Zaccolo groups reveals that a prototypical anchoring protein, known to be responsible for regulating several important physiological processes, also orchestrates the formation of two important universal second messengers.